Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Adult Lymphomas

10 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

COGAHOD04B1

10/05/2011

AHOD04B1 - Hodgkin Disease (HD) Banking Study

Treatment

VICCHEM1463

11/18/2014

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom's Macroglobulinemia

Treatment

VICCHEM1402

09/15/2014

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Treatment

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Treatment

VICCHEM13106

04/09/2014

A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT

Treatment

VICCHEM1392

03/12/2014

A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

Treatment

VICCHEM12103

12/31/2013

Multi-center Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop

Treatment

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Treatment

VICCHEM1284

06/05/2013

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Treatment

VICCHEM1146

08/14/2012

Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma